Thesis (M.S.)--Michigan State University. Dept. of Chemical Engineering and Material Science, 2008. / Title from PDF t.p. (viewed on July 29, 2009) Includes bibliographical references (p. 34-41). Also issued in print.

Thesis (Ph. D.)--West Virginia University, 2006. / Title from document title page. Document formatted into pages; contains xi, 183 p. : ill. (some col.). Vita. Includes abstract. Includes bibliographical references.

Thesis (Ph. D.)--West Virginia University, 1999. / Title from document title page. Document formatted into pages; contains x, 125 p. : ill. Vita. Includes abstract. Includes bibliographical references.

Thesis (Ph. D.)--West Virginia University, 2009. / Title from document title page. Document formatted into pages; contains viii, 141 p. : ill. (some col.). Includes abstract. Includes bibliographical references.

Introdução: O carcinoma de células escamosas da via aerodigestiva superior (VADS) geralmente é unifocal e advém da progressão das lesões pré-neoplásicas. O risco de segundos tumores primários é de 3 a 7% ao ano para pacientes tratados previamente de câncer da VADS, sendo importante avançar em estratégias de quimioprevenção. Nos estudos clínicos realizados, as drogas promissoras mostraramse ineficazes quando aplicadas em doses baixas para minimizar a toxicidade. Neste trabalho, ácidos graxos poliinsaturados ômega-3 (óleo de peixe) e pioglitazone, um agonista PPAR-?, foram utilizados com intenção quimiopreventiva, em modelo animal de carcinogênese da VADS, induzida com o uso de 4- nitroquinolina-1-óxido (4-NQO). Métodos: Camundongos Swiss foram submetidos à indução tumoral com 4-NQO nas doses: 25, 50 ou 100 g/ml diluído em água por 8 semanas. Quimioprevenção foi testada com óleo de peixe nas concentrações de 10% ou 5%. Também foi realizada, em outros grupos, quimioprevenção com pioglitazone nas concentrações de 300 ppm ou 100 ppm. A quimioprevenção foi realizada na iniciação e pós-iniciação tumorais (por 32 semanas) ou apenas na pós- iniciação (por 24 semanas). Resultados: As incidências de neoplasias oral e esofágica foram, respectivamente, similares entre os grupos 4-NQO 100 77,7% e 55,5% e 4-NQO 50 72,9% e 37,8%. O grupo 4-NQO 25, ao ser observado 24 semanas a mais, obteve 78,2% de neoplasia oral e 34,7% de esofágica. A mortalidade por câncer nas 24 semanas após o término do 4-NQO foi de 55,6% no grupo 4-NQO 100, de 11,6% no 4-NQO 50 e de 13,6% no 4-NQO 25; sendo significante na comparação entre os grupos 100 com 50 (p<0,01) e 100 com 25 (p<0,01). Assim, foi observado que 4- NQO 100 g/ml gerou uma mortalidade mais acelerada neste grupo. A maioria dos animais desenvolvia lesões invasoras em mais de um órgão ou a associação destas com pré-neoplásicas. A incidência de neoplasia oral foi similar na comparação entre o grupo 4-NQO 100 (77,7%) com óleo de peixe 10% (80%) p=1,00 e com o grupo pioglitazone 300 ppm (61,1%) p=0,27. Entre os grupos 4-NQO 50 com óleo de peixe 5% (controle - 72,9%, com óleo de peixe na pós- iniciação - 84,2% e com óleo de peixe na iniciação e pós- iniciação - 64,7%) p=0,34 e entre os grupos 4-NQO 50 com pioglitazone 100 ppm (controle - 72,9%, com pioglitazone na pós-iniciação - 76,1% e com pioglitazone na iniciação e pós-iniciação - 62,5%) p=0,63, a incidência de neoplasia oral foi semelhante na comparação entre os grupos. A presença de neoplasia esofágica não diferiu entre o grupo 4-NQO 100 (55,5%) com óleo de peixe 10% (50%) p=0,73 e com o grupo pioglitazone 300 ppm (50%) p=0,73; e foi também similar entre os grupos 4-NQO 50 com pioglitazone 100 ppm (controle - 37,8%, com pioglitazone na pós- iniciação - 57,1% e com pioglitazone na iniciação e pós- iniciação - 31,2%) - p=0,22; porém diferiu nos grupos 4-NQO 50 com óleo de peixe 5% (controle37,8%, com óleo de peixe na pós-iniciação68,4% e com óleo de peixe na iniciação e pós- iniciação29,4%), sendo estatisticamente significante - p=0,02. Interessante foi a observação de que o grupo que realizou quimioprevenção com pioglitazone desenvolveu câncer gástrico na mesma proporção dos demais grupos, porém apresentou uma doença mais agressiva, com disseminação metastática, fato não observado nos outros grupos. Considerando-se a sobrevida, não foi observada diferença estatística significante nas 24 semanas comparando-se os grupos 4-NQO 100 e entre os grupos 4-NQO 50 com ou sem quimioprevenção com óleo de peixe ou com pioglitazone. Conclusão: A indução tumoral com 4-NQO, independente da dose, foi obtida com sucesso em camundongos Swiss. Neste estudo, não foram observados efeitos de quimioprevenção do óleo de peixe e do pioglitazone nas diferentes fases da carcinogênese estudadas. O óleo de peixe na pós-iniciação pode ter potencializado a ação carcinogênica do 4-NQO no esôfago, assim como a associação do 4-NQO com o pioglitazone possa ter criado um novo modelo de carcinogênese gástrica, não vista nos grupos que não receberam esta associação. / Introduction: The squamous cell carcinoma of the upper aerodigestive tract (UADT) is generally unifocal and arises from the progression of premalignant lesions. Between 3% to 7% of patients with head and neck carcinoma will develop subsequent primary tumors of the UADT annually; therefore, the importance of advancing in new chemopreventive strategies is unquestionable. In clinical studies, promising drugs were ineffective when used at low doses to minimize toxicity. In the present study, the potential chemopreventive effects of polyunsaturated fatty acids omega-3 (fish oil) and of a PPAR-? ligand (pioglitazone) were tested in an animal model of UADT carcinogenesis induced by 4-nitroquinoline-1-oxide (4-NQO) in Swiss mice. Methods : The animals underwent tumor induction with 25, 50 or 100 g/ml of 4-NQO diluted in water for eight weeks. Chemoprevention was tested with 10% or 5% fish oil and with 300 ppm or 100 ppm pioglitazone in other groups. Chemoprevention was conducted on tumor initiation and postinitiation for 32 weeks or only on postinitiation for 24 weeks. Results : The incidence rates of oral and esophageal neoplasms were similar between groups 4-NQO 100 (77,7% and 55,5%, respectively) and 4-NQO 50 (72,9% and 37,8%, respectively). Group 4-NQO 25 was followed for 24 weeks longer than the others and showed incidence rates of 78,2% for oral neoplasia and 34,7% for esophageal neoplasia. Cancer-related mortality rates in the 24 weeks following the conclusion of the tumor induction phase were 55,6%, 11,6% and 13,6% in groups 4-NQO 100, 4-NQO 50 and 4-NQO 25, respectively. The differences were statistically significant when comparing groups 100 with 50 (p<0,01) and 100 with 25 (p<0,01). The dose of 100 g/ml 4-NQO led to faster mortality compared with 50 g/ml or 25 g/ml 4-NQO. Most animals developed invasive lesions in more than one site of the UADT or, more frequently, an association of premalignant and malignant lesions. The incidence of oral neoplasia was similar in the comparison of the control group 4-NQO 100 with 10% fish oil (77,7% vs 80%, p=1,00) or with 300 ppm pioglitazone (77,7% vs 61,1%, p=0,27). Results were also similar when comparing 4-NQO 50 groups with 5% fish oil (control72,9%, fish oil on postinitiation84,2%, and fish oil on initiation and postinitiation64,7%, p=0,34), and between 4-NQO 50 groups with 100 ppm pioglitazone (control72,9%, pioglitazone on postinitiation76,1%, and pioglitazone on initiation and postinitiation62,5%, p=0,63). The incidence of esophageal neoplasia reached no statistical difference either when 4-NQO 100 control group was compared with 10% fish oil (55,5% vs 50%, p=0,73) or with 300 ppm pioglitazone (55,5% vs 50%, p=0,73). The same was true between 4-NQO 50 groups with 100 ppm pioglitazone (control37,8%, pioglitazone on postinitiation57,1%, and pioglitazone on initiation and postinitiation31,2%, p=0,22). Statistically significant differences were found between 4-NQO 50 groups with 5% fish oil (control37,8%, fish oil on postinitiation68,4%, and fish oil on initiation and postinitiation29,4%, p=0,02). Interestingly, the group receiving chemoprevention with 300 ppm pioglitazone had a gastric cancer incidence rate comparable to that of other groups, but with more aggressive disease and metastatic dissemination, unlike the others. No statistically significant differences were found in the survival rates for the 24-week period after induction when comparing the control groups 4-NQO 100 and 4-NQO 50 with their respective experimental groups, which received chemoprevention with fish oil or pioglitazone. Conclusions : Tumor induction with 4-NQO was successfully achieved in Swiss mice, regardless of the dose. In this study, no chemopreventive effects of fish oil or pioglitazone were observed either on postinitiation or on initiation and postinitiation. The introduction of fish oil on the postinitiation phase may have potentialized the carcinogenic action of 4-NQO on the esophageal epithelium; the same can be said about the association of 4-NQO and pioglitazone, which may have created a new model of gastric carcinogenesis not seen in the groups that did not receive that combination of drugs.

Introdução: O carcinoma de células escamosas da via aerodigestiva superior (VADS) geralmente é unifocal e advém da progressão das lesões pré-neoplásicas. O risco de segundos tumores primários é de 3 a 7% ao ano para pacientes tratados previamente de câncer da VADS, sendo importante avançar em estratégias de quimioprevenção. Nos estudos clínicos realizados, as drogas promissoras mostraramse ineficazes quando aplicadas em doses baixas para minimizar a toxicidade. Neste trabalho, ácidos graxos poliinsaturados ômega-3 (óleo de peixe) e pioglitazone, um agonista PPAR-?, foram utilizados com intenção quimiopreventiva, em modelo animal de carcinogênese da VADS, induzida com o uso de 4- nitroquinolina-1-óxido (4-NQO). Métodos: Camundongos Swiss foram submetidos à indução tumoral com 4-NQO nas doses: 25, 50 ou 100 g/ml diluído em água por 8 semanas. Quimioprevenção foi testada com óleo de peixe nas concentrações de 10% ou 5%. Também foi realizada, em outros grupos, quimioprevenção com pioglitazone nas concentrações de 300 ppm ou 100 ppm. A quimioprevenção foi realizada na iniciação e pós-iniciação tumorais (por 32 semanas) ou apenas na pós- iniciação (por 24 semanas). Resultados: As incidências de neoplasias oral e esofágica foram, respectivamente, similares entre os grupos 4-NQO 100 77,7% e 55,5% e 4-NQO 50 72,9% e 37,8%. O grupo 4-NQO 25, ao ser observado 24 semanas a mais, obteve 78,2% de neoplasia oral e 34,7% de esofágica. A mortalidade por câncer nas 24 semanas após o término do 4-NQO foi de 55,6% no grupo 4-NQO 100, de 11,6% no 4-NQO 50 e de 13,6% no 4-NQO 25; sendo significante na comparação entre os grupos 100 com 50 (p<0,01) e 100 com 25 (p<0,01). Assim, foi observado que 4- NQO 100 g/ml gerou uma mortalidade mais acelerada neste grupo. A maioria dos animais desenvolvia lesões invasoras em mais de um órgão ou a associação destas com pré-neoplásicas. A incidência de neoplasia oral foi similar na comparação entre o grupo 4-NQO 100 (77,7%) com óleo de peixe 10% (80%) p=1,00 e com o grupo pioglitazone 300 ppm (61,1%) p=0,27. Entre os grupos 4-NQO 50 com óleo de peixe 5% (controle - 72,9%, com óleo de peixe na pós- iniciação - 84,2% e com óleo de peixe na iniciação e pós- iniciação - 64,7%) p=0,34 e entre os grupos 4-NQO 50 com pioglitazone 100 ppm (controle - 72,9%, com pioglitazone na pós-iniciação - 76,1% e com pioglitazone na iniciação e pós-iniciação - 62,5%) p=0,63, a incidência de neoplasia oral foi semelhante na comparação entre os grupos. A presença de neoplasia esofágica não diferiu entre o grupo 4-NQO 100 (55,5%) com óleo de peixe 10% (50%) p=0,73 e com o grupo pioglitazone 300 ppm (50%) p=0,73; e foi também similar entre os grupos 4-NQO 50 com pioglitazone 100 ppm (controle - 37,8%, com pioglitazone na pós- iniciação - 57,1% e com pioglitazone na iniciação e pós- iniciação - 31,2%) - p=0,22; porém diferiu nos grupos 4-NQO 50 com óleo de peixe 5% (controle37,8%, com óleo de peixe na pós-iniciação68,4% e com óleo de peixe na iniciação e pós- iniciação29,4%), sendo estatisticamente significante - p=0,02. Interessante foi a observação de que o grupo que realizou quimioprevenção com pioglitazone desenvolveu câncer gástrico na mesma proporção dos demais grupos, porém apresentou uma doença mais agressiva, com disseminação metastática, fato não observado nos outros grupos. Considerando-se a sobrevida, não foi observada diferença estatística significante nas 24 semanas comparando-se os grupos 4-NQO 100 e entre os grupos 4-NQO 50 com ou sem quimioprevenção com óleo de peixe ou com pioglitazone. Conclusão: A indução tumoral com 4-NQO, independente da dose, foi obtida com sucesso em camundongos Swiss. Neste estudo, não foram observados efeitos de quimioprevenção do óleo de peixe e do pioglitazone nas diferentes fases da carcinogênese estudadas. O óleo de peixe na pós-iniciação pode ter potencializado a ação carcinogênica do 4-NQO no esôfago, assim como a associação do 4-NQO com o pioglitazone possa ter criado um novo modelo de carcinogênese gástrica, não vista nos grupos que não receberam esta associação. / Introduction: The squamous cell carcinoma of the upper aerodigestive tract (UADT) is generally unifocal and arises from the progression of premalignant lesions. Between 3% to 7% of patients with head and neck carcinoma will develop subsequent primary tumors of the UADT annually; therefore, the importance of advancing in new chemopreventive strategies is unquestionable. In clinical studies, promising drugs were ineffective when used at low doses to minimize toxicity. In the present study, the potential chemopreventive effects of polyunsaturated fatty acids omega-3 (fish oil) and of a PPAR-? ligand (pioglitazone) were tested in an animal model of UADT carcinogenesis induced by 4-nitroquinoline-1-oxide (4-NQO) in Swiss mice. Methods : The animals underwent tumor induction with 25, 50 or 100 g/ml of 4-NQO diluted in water for eight weeks. Chemoprevention was tested with 10% or 5% fish oil and with 300 ppm or 100 ppm pioglitazone in other groups. Chemoprevention was conducted on tumor initiation and postinitiation for 32 weeks or only on postinitiation for 24 weeks. Results : The incidence rates of oral and esophageal neoplasms were similar between groups 4-NQO 100 (77,7% and 55,5%, respectively) and 4-NQO 50 (72,9% and 37,8%, respectively). Group 4-NQO 25 was followed for 24 weeks longer than the others and showed incidence rates of 78,2% for oral neoplasia and 34,7% for esophageal neoplasia. Cancer-related mortality rates in the 24 weeks following the conclusion of the tumor induction phase were 55,6%, 11,6% and 13,6% in groups 4-NQO 100, 4-NQO 50 and 4-NQO 25, respectively. The differences were statistically significant when comparing groups 100 with 50 (p<0,01) and 100 with 25 (p<0,01). The dose of 100 g/ml 4-NQO led to faster mortality compared with 50 g/ml or 25 g/ml 4-NQO. Most animals developed invasive lesions in more than one site of the UADT or, more frequently, an association of premalignant and malignant lesions. The incidence of oral neoplasia was similar in the comparison of the control group 4-NQO 100 with 10% fish oil (77,7% vs 80%, p=1,00) or with 300 ppm pioglitazone (77,7% vs 61,1%, p=0,27). Results were also similar when comparing 4-NQO 50 groups with 5% fish oil (control72,9%, fish oil on postinitiation84,2%, and fish oil on initiation and postinitiation64,7%, p=0,34), and between 4-NQO 50 groups with 100 ppm pioglitazone (control72,9%, pioglitazone on postinitiation76,1%, and pioglitazone on initiation and postinitiation62,5%, p=0,63). The incidence of esophageal neoplasia reached no statistical difference either when 4-NQO 100 control group was compared with 10% fish oil (55,5% vs 50%, p=0,73) or with 300 ppm pioglitazone (55,5% vs 50%, p=0,73). The same was true between 4-NQO 50 groups with 100 ppm pioglitazone (control37,8%, pioglitazone on postinitiation57,1%, and pioglitazone on initiation and postinitiation31,2%, p=0,22). Statistically significant differences were found between 4-NQO 50 groups with 5% fish oil (control37,8%, fish oil on postinitiation68,4%, and fish oil on initiation and postinitiation29,4%, p=0,02). Interestingly, the group receiving chemoprevention with 300 ppm pioglitazone had a gastric cancer incidence rate comparable to that of other groups, but with more aggressive disease and metastatic dissemination, unlike the others. No statistically significant differences were found in the survival rates for the 24-week period after induction when comparing the control groups 4-NQO 100 and 4-NQO 50 with their respective experimental groups, which received chemoprevention with fish oil or pioglitazone. Conclusions : Tumor induction with 4-NQO was successfully achieved in Swiss mice, regardless of the dose. In this study, no chemopreventive effects of fish oil or pioglitazone were observed either on postinitiation or on initiation and postinitiation. The introduction of fish oil on the postinitiation phase may have potentialized the carcinogenic action of 4-NQO on the esophageal epithelium; the same can be said about the association of 4-NQO and pioglitazone, which may have created a new model of gastric carcinogenesis not seen in the groups that did not receive that combination of drugs.

Thesis (Ph. D.)--West Virginia University, 2000. / Title from document title page. Document formatted into pages; contains xi, 126 p. : ill. Vita. Includes abstract. Includes bibliographical references (p. 93-115).

Objetivo: analisar o consumo alimentar de energia, macronutrientes e ácidos graxos, de gestantes com insuficiência placentária, comparando com gestantes sem esta complicação obstétrica. Métodos: Estudo prospectivo, transversal e caso-controle realizado no período de fevereiro de 2012 a setembro de 2013, que incluiu gestantes que preencheram os seguintes critérios: gestação com feto único e vivo; idade gestacional superior a 26 semanas completas; diagnóstico de insuficiência placentária caracterizada pelo exame de Doppler de artéria umbilical com índice de pulsatilidade acima do p95; morfologia fetal normal ao exame de ultrassonografia; ausência de diagnóstico de diabetes; não suplementação pré-natal com ácidos graxos. Foram adotados os seguintes critérios de exclusão: diagnóstico pós-natal de anomalia do recém-nascido. O estado nutricional da gestante foi avaliado pelo índice de massa corporal (IMC) e o consumo dietético foi investigado pela aplicação do questionário de frequência alimentar, analisado pelo programa Avanutri Revolution versão 4.0, pelo qual se obteve o consumo de energia, macronutrientes (carboidratos, proteínas e lipídios) e de ácidos graxos (saturados, poli-insaturados e monoinsaturados). Foram analisados os valores absolutos obtidos e a % do valor energético total (VET) da dieta. Resultados: Foram incluídas 21 gestantes no grupo com insuficiência placentária e 21 gestantes no grupo controle. Não se constatou diferença na mediana do IMC na comparação entre os grupos (grupo estudo=26,5 kg/m2, grupo controle=28,0kg/m2; P=0,563). Houve diferença significativa na comparação do grupo com insuficiência placentária com o grupo controle na análise do consumo alimentar de: energia (2002 kcal vs. 1515 kcal, p= 0,021). Com relação ao consumo de ácidos graxos, houve diferença significativa na comparação da % do VET entre os grupos com insuficiência placentária e controle: saturados (11,5% vs. 9,3%; p=0,043); poli saturados (2,7% vs. 3,6%; p=0,029); monoinsaturados (1,2 % vs. 2,1%; p= 0,005). Não foram encontradas diferenças significativas na qualidade da dieta entre os grupos quanto ao consumo avaliado de acordo com a % do VET: carboidratos (51,5% vs. 51,8%; p= 0,831); proteínas (15,3% vs. 16,1%; p= 0,458); lipídios totais (37,8% vs. 33,0%; p=0,831). Conclusão: Gestantes com o diagnóstico de insuficiência placentária relatam consumo alimentar diferente de gestantes que não apresentam esse diagnóstico, com dieta de ácidos graxos com qualidade inferior, notadamente com maior consumo de ácidos graxos saturados, e menor consumo de poli-insaturados e monoinsaturados, além de maior consumo de energia / Objective: To analyze the dietary intake of energy, macronutrients and fatty acids of pregnant women with placental insufficiency, and to compare with pregnant women without this obstetric complication Methods : A prospective, cross-sectional and case -control study from February 2012 to September 2013, which included women who met the following criteria: singleton pregnancy with fetus alive; above 26 weeks gestation; diagnosis of placental insufficiency characterized by umbilical artery Doppler presenting pulsatility index above the p95; normal fetal morphology at ultrasound, absence of diabetes, absence of prenatal supplementation with fatty acids. We used the following exclusion criteria: neonatal diagnosis of malformation. The maternal nutritional status was assessed by body mass index (BMI) and dietary intake was investigated by applying the food frequency questionnaire analyzed by the program Avanutri Revolution version 4.0 , which was obtained by the consumption of energy, macronutrients (carbohydrates, proteins and lipids) and fatty acids (saturated, polyunsaturated and monounsaturated). We analyzed the absolute values and the % of total energy value (TEV). Results: We included 21 pregnant women in the study group with placental insufficiency and 21 pregnant women in the control group. There was no difference in median BMI between the groups (study group = 26.5 kg/m2, control group = 28.0 kg/m2, P = 0.563). Significant difference was found when the group with placental insufficiency was compared with the control group in food consumption of energy (2002kcal vs. 1515 kcal, p = 0.021). With regard to the consumption of fatty acids, there was a significant difference in the percentages of daily energy intake between the group with placental insufficiency and control group: saturated fatty acids(11.5% vs. . 9.3% , p = 0.043), polyunsaturated fatty acids(2.7 % vs. 3.6% , p = 0.029), monounsaturated fatty acids(1.2% vs. 2.1% , p = 0.005). There were no significant differences in diet quality between the groups regarding the consumption evaluated according to the % of VET: carbohydrates ( 51.5 % vs. 51.8 %, p = 0.831 ), protein (15.3 % vs. 16.1 %, p = 0.458), total fat (37.8 % vs. 33.0 %, p = 0.831) . Conclusion: Pregnant women with the diagnosis of placental insufficiency reported food consumption other than pregnant women who do not have this diagnosis with lower quality of dietary fatty acids consumption, especially with higher intake of saturated fatty acids , and lower intake of polyunsaturated and monounsaturated fatty acids, and greater energy consumption

A obesidade é uma doença crônica com complicações para a qual se busca o tratamento e a prevenção. A gordura visceral é um órgão endócrino de armazenamento hormonal e produtor de adipocinas inflamatórias, tornando o obeso portador de inflamação crônica, que por sua vez é uma das características da aterogênese e do envelhecimento. Os níveis aumentados de interleucina-6 e fator de necrose tumoral-alfa, citocinas multifuncionais, estão associados à morbi-mortalidade em idosos e à patogênese da aterosclerose. Nos dias atuais, a alimentação mundial é caracterizada pelo aumento do consumo de gordura saturada e gorduras trans, bem como pela redução do consumo de ácidos graxos ômega-3. O desequilíbrio na relação ômega-6/ômega-3 propicia um ambiente de inflamação crônica, sendo o estímulo inicial para doenças degenerativas. A substituição de gorduras saturadas por ácidos graxos poliinsaturados, de ácido alfa- linolênico (ALA) - ômega-3, e de ácido graxo monoinsaturado (ácido oléico - ômega- 9), parece estar associada à redução do risco de doença cardiovascular. Entre duas fontes de ácido eicosapentaenóico e ácido docosahexaenóico, os ácidos graxos ômega-3 provenientes de peixes e o ALA das fontes vegetais, este último é mais acessível financeiramente e amplamente disponível no mundo todo. Este estudo foi desenhado para avaliar comparativamente o efeito do aumento do consumo de ALA proveniente de fontes vegetais sobre os indicadores inflamatórios e a reatividade endotelial em pacientes idosos e obesos ou com sobrepeso. Foram selecionados 79 pacientes para receber doses diárias de óleo de linhaça, óleo de oliva e óleo de girassol por 12 semanas consecutivas. Foram realizadas medidas antropométricas, bioquímicas e de reatividade endotelial antes e após a intervenção, sem nenhuma modificação na dieta dos participantes ou em suas medicações utilizadas, não havendo mudanças antropométricas após a conclusão do estudo. Houve melhora em alguns parâmetros bioquímicos com o óleo de linhaça, que reduziu os níveis de PCRus, C3, C4 e fibrinogênio; com o óleo de girassol, que reduziu os níveis de leptina, ApoB e também a relação Apo B/ApoA1; e com o óleo de oliva que beneficiou a relação Apo B/ApoA1 e os níveis de C4. A espessura da artéria carótida também teve melhora significativa com os três óleos suplementados, mais acentuada com o óleo de linhaça e o óleo de oliva. Além disto, o óleo de girassol melhorou significativamente a distensibilidade da parede arterial e da vasodilatação fluxo-mediada (VFM) e o óleo de oliva apresentou tendência de melhora na VFM. Concluímos que a suplementação de ácidos graxos insaturados provenientes dos três óleos vegetais atenuou o quadro pró-inflamatório e pró-trombótico. Ocorreu melhora do perfil de marcadores bioquímicos e resultados significativos estatisticamente nos marcadores de reatividade endotelial como redução da espessura da íntima-média da artéria carótida, melhora da distensibilidade da parede arterial e melhora da funcionalidade medida pela VFM. Foi benéfica sua introdução à dieta, a fim de reduzir o risco cardiovascular em idosos portadores de obesidade ou sobrepeso / Obesity is a chronic disease with complications for which treatment and prevention are sought. Visceral fat is an endocrine organ of hormonal storage and a producer of inflammatory adipokines, leading to chronic inflammation in the obese person, which in turn is one of the characteristics of atherogenesis and aging. Increased levels of multifunctional cytokines, interleukin-6 and tumor necrosis factor-alfa are associated with morbidity and mortality in the elderly, and in the pathogenesis of atherosclerosis. Currently, food worldwide is characterized by increased consumption of saturated and trans fats, as well as reduced consumption of omega-3 fatty acids. Imbalance in the omega-6/omega-3 ratio provides an environment of chronic inflammation, and the initial stimulus for degenerative diseases. The substitution of saturated fats by polyunsaturated fatty acids, alfa-linolenic acid (ALA)- omega-3, and mono-unsaturated fatty acid (omega-9 fatty acids), seems to be associated with reduced risk of cardiovascular disease. Obtaining alfa-linolenic acid from vegetable sources is more financially accessible and widely available worldwide than omega-3 fatty acids from fish; both are sources of eicosapentaenoic acid and docosahexaenoic acid. This study was designed to comparatively evaluate the effect of increased ALA consumption, derived from vegetables, on inflammatory indicators and the endothelial reactivity in obese or overweight elderly patients. Seventy nine patients were selected to receive daily doses of linseed oil, olive oil and sunflower oil for 12 consecutive weeks. Anthropometric, biochemical and endothelial reactivity measurements were performed before and after the intervention, without any changes in the participants\' diet or in their medications, and no anthropometric changes were identified after the conclusion of the study. Improvement in some biochemical parameters were identified with linseed oil, which reduced the levels of C-reactive protein, C3, C4 and fibrinogen; with sunflower oil, which reduced levels of leptin, ApoB and also ApoB/ApoA1 ratio; and with the olive oil that improved the ApoB/ApoA1 ratio and the C4 levels. Carotid artery thickness also showed a significant improvement with the three supplemented oils, and was more accentuated with linseed oil and olive oil. In addition, sunflower oil significantly improved the distensibility of the arterial wall and its flow-mediated dilatation (FMD), and olive oil showed a tendency for improvement in FMD. We concluded that the supplementation of unsaturated fatty acids from the three vegetable oils attenuated the pro-inflammatory and prothrombotic conditions. An improvement in the profile of biochemical markers and statistically significant results was identified in markers of endothelial reactivity, such as reduction of carotid artery intima-media thickness, improvement of the arterial wall distensibility and the endothelial function measured by FMD. The introduction of unsaturated fatty acids in the diet was beneficial, in order to reduce cardiovascular risk in obese or overweight elderly

by Kwan Kwok Yiu. / Thesis (M.Phil.)--Chinese University of Hong Kong, 1997. / Includes bibliographical references (leaves 145-155). / Acknowledgment --- p.i / Abstract --- p.ii / List of Tables --- p.vii / List of Figures --- p.x / List of Abbreviations --- p.xii / Chapter Chapter 1 --- Literature review / Chapter 1.1 --- Historical background --- p.1 / Chapter 1.2 --- Chemistry of trans and cis fatty acids --- p.3 / Chapter 1.3 --- Dietary source of trans fatty acids --- p.6 / Chapter 1.4 --- Consumption of trans fatty acids among Western countries --- p.9 / Chapter 1.5 --- Current health concern for excessive intake of trans fatty acids --- p.10 / Chapter 1.6 --- Metabolism of trans fatty acids --- p.13 / Chapter 1.6.1 --- Absorption --- p.15 / Chapter 1.6.2 --- Oxidation --- p.15 / Chapter 1.6.3 --- Incorporation --- p.16 / Chapter 1.6.4 --- Selectivity --- p.17 / Chapter 1.7 --- Impact of trans fatty acids on essential fatty acid metabolism --- p.19 / Chapter 1.8 --- Desaturation and elongation of trans fatty acids --- p.21 / Chapter 1.9 --- Trans fatty acids and neonatal growth --- p.23 / Chapter Chapter 2 --- Amount of trans fatty acids in Hong Kong fast foods / Chapter 2.1 --- Introduction --- p.25 / Chapter 2.2 --- Objective --- p.25 / Chapter 2.3 --- Materials and methods --- p.26 / Chapter 2.4 --- Results --- p.27 / Chapter 2.5 --- Discussion --- p.31 / Chapter Chapter 3 --- Cross-cultural study of trans fatty acids in human milk / Chapter 3.1 --- Introduction --- p.35 / Chapter 3.2 --- Objective --- p.35 / Chapter 3.3 --- Materials and methods --- p.36 / Chapter 3.4 --- Results / Chapter 3.4.1 --- Dietary information --- p.38 / Chapter 3.4.2 --- Fatty acid composition of Chinese and Canadian human milk --- p.40 / Chapter 3.4.3 --- Difference between Chinese and Canadian human milk --- p.40 / Chapter 3.4.4 --- Difference between Hong Kong and Chongqing Chinese human milk --- p.43 / Chapter 3.4.5 --- The change in milk fat and LCPUFA as lactation progresses --- p.43 / Chapter 3.5 --- Discussion / Chapter 3.5.1 --- Trans fatty acids in human milk --- p.46 / Chapter 3.5.2 --- Content of LCPUFA in human milk --- p.47 / Chapter 3.5.3 --- Content of 18:2n-6 in human milk --- p.48 / Chapter 3.5.4 --- Fat content in Hong Kong and Chongqing Chinese human milk --- p.49 / Chapter 3.6 --- Conclusion --- p.50 / Chapter Chapter 4 --- Trans fatty acids and maternal and neonatal essential fatty acid metabolism / Chapter 4.1 --- Introduction --- p.51 / Chapter 4.2 --- Objectives --- p.53 / Chapter 4.3 --- Materials and methods --- p.53 / Chapter 4.4 --- Results / Chapter 4.4.1 --- Experiment1 / Chapter 4.4.1.1 --- Relationship between the trans fatty acids in maternal diet and those in milk --- p.64 / Chapter 4.4.1.2 --- Relationship between the trans fatty acids in maternal diet and those in neonatal liver --- p.64 / Chapter 4.4.1.3 --- Content of 20:4n-6 in milk and in neonatal liver relative to that in maternal diet --- p.72 / Chapter 4.4.2 --- Experiment2 / Chapter 4.4.2.1 --- Amount of trans fatty acids in rat milk --- p.75 / Chapter 4.4.2.2 --- Trans fatty acids in rat liver phospholipids --- p.75 / Chapter 4.4.2.3 --- Linoleic acid (18:2n-6) content in rat and its relation to maternal diets --- p.86 / Chapter 4.4.2.4 --- Content of 20:4n-6 in rat milk --- p.86 / Chapter 4.4.2.5 --- Content of20:4n-6 in rat liver --- p.89 / Chapter 4.4.2.6 --- Suppression of the synthesis of 20:4t isomers in maternal and neonatal liver --- p.89 / Chapter 4.5 --- Discussion / Chapter 4.5.1 --- Relationship between fatty acid composition of diet and that of milk --- p.93 / Chapter 4.5.2 --- 20:4n-6 in rat milk --- p.95 / Chapter 4.5.3 --- Transfer of trans fatty acids from maternal diet to neonatal liver phospholipids --- p.98 / Chapter 4.5.4 --- The inhibitory effect of trans fatty acids on synthesis of 20:4n-6 in neonatal liver --- p.99 / Chapter 4.5.5 --- Effect of 18:2n-6 supplement on 20:4n-6 level of neonatal liver --- p.101 / Chapter 4.5.6 --- Suppression of 18:2n-6 supplement on synthesis of 20:4t isomers --- p.101 / Chapter 4.6 --- Conclusion --- p.104 / Chapter Chapter 5 --- Accumulation and turnover of trans fatty acids / Chapter 5.1 --- Introduction --- p.105 / Chapter 5.2 --- Objective --- p.105 / Chapter 5.3 --- Materials and methods --- p.106 / Chapter 5.4 --- Results / Chapter 5.4.1 --- Accumulation of trans fatty acids in liver and adipose tissue --- p.108 / Chapter 5.4.2 --- Selectivity of individual 18:2 trans isomersin liver and adipose tissue --- p.112 / Chapter 5.4.3 --- Turnover of trans fatty acids --- p.112 / Chapter 5.4.4 --- Accumulation and turnover of 18:lt in brain --- p.115 / Chapter 5.5 --- Discussion / Chapter 5.5.1 --- Accumulation of trans fatty acids in liver and adipose tissue --- p.120 / Chapter 5.5.2 --- Turnover of trans fatty acids --- p.122 / Chapter 5.5.3 --- Accumulation and turnover of trans fatty acidsin brain --- p.124 / Chapter 5.6 --- Conclusion --- p.125 / Chapter Chapter 6 --- In vivo Oxidation of trans fatty acids in rat / Chapter 6.1 --- Introduction --- p.126 / Chapter 6.2 --- Objective --- p.127 / Chapter 6.3 --- Materials and methods --- p.127 / Chapter 6.4 --- Results --- p.129 / Chapter 6.4.1 --- Apparent oxidation of saturated fatty acids --- p.136 / Chapter 6.4.2 --- Apparent oxidation of 18:lt relative to 18:ln-9 --- p.136 / Chapter 6.4.3 --- Oxidation of 18:2t isomers relative to 18:2n-6 --- p.137 / Chapter 6.4.4 --- Effect of 18:2n-6 supplement in PHCO diet on oxidation per se --- p.137 / Chapter 6.5 --- Discussion --- p.138 / Chapter 6.5.1 --- Oxidation of 18:lt and 18:2t isomers --- p.139 / Chapter 6.5.2 --- Effect of 18:2n-6 supplement on oxidation per se --- p.140 / Chapter 6.6 --- Conclusion --- p.141 / General conclusion --- p.142 / References --- p.145